Shuimu is a rapidly evolving global cryo-EM & AI platform for early drug discovery, founded in 2017 and headquartered in Beijing, China. Shuimu drives innovation to accelerate the development of innovative drugs. Shuimu leverages the power of cutting-edge cryo-EM & AI technology to help its partners gain key structural insights into the target proteins and complexes. The team consists of top talents with global backgrounds in the field of structural biology, machine learning, protein science, and drug chemistry. Learn more about Shuimu and check out its cryo-EM precision imaging platform by visiting shuimubio.com.